Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that familiar routine of meetings, deadlines, and the like has returned. You knew this would happen, even if it is high vacation season. After all, the world is still spinning. So please join us as we fire up the coffee kettle to brew some cups of stimulation and hunker down for another busy day. Toward that end, we have assembled some tidbits to help you along. Hope your day is smashing and do keep in touch …
Glass Lewis recommended Cigna (CI) shareholders vote in favor of the proposed $52 billion acquisition of Express Scripts (ESRX), the second proxy advisory firm to support the deal, Reuters writes. Carl Icahn, who owns shares in Cigna, opposes the deal, but hedge fund Glenview Capital Management, which also has a stake in the health insurer, has backed the purchase. On Friday, Institutional Shareholder Services also extended support. Icahn, who has a 0.56 percent stake in Cigna, cited regulatory hurdles and a growing threat from Amazon as reasons to vote it down.
As last week ended, the Food and Drug Administration approved two notable treatments. One is an Alnylam Pharmaceuticals’ (ALNY) medicine, which is the first treatment to rely on a Nobel-prize-winning technique known as RNA interference that silences disease-causing genes, STAT notes. The agency also approved an Amicus Therapeutics (FOLD) drug called Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs, Reuters reports.
About the Author Reprints
